{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:37:35Z","timestamp":1783489055002,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Lenvatinib is a multityrosine kinase inhibitor approved for progressive radioiodine refractory differentiated thyroid cancer (RAI-R-DTC). Despite its efficacy, most of the initial experiences showed global inferior results if compared with SELECT study. Baseline disease stages, previous systemic treatments and baseline patients\u2019 characteristics may affect response to therapy. The aim of our study was to review relevant clinical outcomes, identifying survival predictors, of a single center cohort of patients with advanced thyroid cancer treated with Lenvatinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Twenty-two patients with progressive RAIR-R-DTC treated with Lenvatinib were retrospectively included. For each patient, we reviewed the main clinical baseline characteristics, including nutritional status. We evaluated the latter by using CONtrolling NUTritional status (CONUT) score. Clinical outcomes were overall survival (OS) and progression free survival (PFS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At the time of analysis, 14 patients (63.6%) were alive with a median OS of 54 months (95% CI 20.35\u201387.65 months). Progression occurred in 16 patients (72.7%) with a median PFS of 21 months (95% CI 0\u201347.33 months). Nineteen out of 22 patients (86.4%) presented at least one adverse event (AE) of any grade. Baseline lower CONUT score significantly correlated with both longer PFS (HR 2.77- 95% CI 1.216\u20136.307, <jats:italic>p<\/jats:italic>\u2009=\u20090.015) and longer OS (HR 4.455\u201395% CI 1.211\u201316.391, <jats:italic>p<\/jats:italic>\u2009=\u20090.025). A significant longer survival was observed in patients with ECOG 0 compared to those with ECOG 1 and in the latter compared to ECOG 2 group (Log-rank test: <jats:italic>p<\/jats:italic>\u2009=\u20090.040). Conversely, higher baseline ECOG Performance Status (PS) correlated with higher severity of AEs (rs 0.468, <jats:italic>p<\/jats:italic>\u2009=\u20090.027). Finally, responder patients showed a significantly better PFS (HR 2.337\u201395% CI 1.091\u20135.006, <jats:italic>p<\/jats:italic>\u2009=\u20090.029).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We confirmed the good efficacy of Lenvatinib treatment in progressive advanced RAI-R-DTCs showing the prognostic value of best tumor response, ECOG PS and CONUT score.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12020-025-04228-5","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T20:48:32Z","timestamp":1744404512000},"page":"143-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictors of response to lenvatinib in advanced differentiated thyroid cancer: focus on the CONUT score"],"prefix":"10.1007","volume":"89","author":[{"given":"Edoardo","family":"Talpacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efisio","family":"Puxeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"4228_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"L. Fugazzola, R. Elisei, D. Fuhrer, B. Jarzab, S. Leboulleux, K. Newbold, J. Smit, 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur. Thyroid. J. 8, 227\u2013245 (2019).","journal-title":"Eur. Thyroid. J."},{"key":"4228_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s13318-017-0403-4","volume":"42","author":"Z Hussein","year":"2017","unstructured":"Z. Hussein, H. Mizuo, S. Hayato, M. Namiki, R. Shumaker, Clinical Pharmacokinetic and pharmacodynamic profile of lenvatinib, an orally active, small-molecule, multitargeted tyrosine kinase inhibitor. Eur. J. Drug. Metab. Pharmacokinet. 42, 903\u2013914 (2017).","journal-title":"Eur. J. Drug. Metab. Pharmacokinet."},{"key":"4228_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4228_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","volume":"25","author":"AG Gianoukakis","year":"2018","unstructured":"A.G. Gianoukakis, C.E. Dutcus, N. Batty, M. Guo, M. Baig, Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr. Relat. Cancer 25, 699\u2013704 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"4228_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","volume":"56","author":"RI Haddad","year":"2017","unstructured":"R.I. Haddad, M. Schlumberger, L.J. Wirth, E.J. Sherman, M.H. Shah, B. Robinson, C.E. Dutcus, A. Teng, A.G. Gianoukakis, S.I. Sherman, Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56, 121\u2013128 (2017).","journal-title":"Endocrine"},{"key":"4228_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/thy.2017.0205","volume":"28","author":"A Berdelou","year":"2018","unstructured":"A. Berdelou, I. Borget, Y. Godbert, T. Nguyen, M.E. Garcia, C.N. Chougnet, A. Ferru, C. Buffet, O. Chabre, O. Huillard, S. Leboulleux, M. Schlumberger, Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 28, 72\u201378 (2018).","journal-title":"Thyroid"},{"key":"4228_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.7150\/jca.22318","volume":"9","author":"C Balmelli","year":"2018","unstructured":"C. Balmelli, N. Railic, M. Siano, K. Feuerlein, R. Cathomas, V. Cristina, C. G\u00fcthner, S. Zimmermann, S. Weidner, M. Pless, F. Stenner, S.I. Rothschild, Lenvatinib in advanced radioiodine-refractory thyroid cancer - a retrospective analysis of the swiss lenvatinib named patient program. J. Cancer 9, 250\u2013255 (2018).","journal-title":"J. Cancer"},{"key":"4228_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.annonc.2021.05.793","volume":"32","author":"L Bargetzi","year":"2021","unstructured":"L. Bargetzi, C. Brack, J. Herrmann, A. Bargetzi, L. Hersberger, M. Bargetzi, N. Kaegi-Braun, P. Tribolet, F. Gomes, C. Hoess, V. Pavlicek, S. Bilz, S. Sigrist, M. Br\u00e4ndle, C. Henzen, R. Thomann, J. Rutishauser, D. Aujesky, N. Rodondi, J. Donz\u00e9, A. Laviano, Z. Stanga, B. Mueller, P. Schuetz, Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial. Ann. Oncol. 32, 1025\u20131033 (2021).","journal-title":"Ann. Oncol."},{"key":"4228_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.603936","volume":"8","author":"E Reber","year":"2021","unstructured":"E. Reber, K.A. Sch\u00f6nenberger, M.F. Vasiloglou, Z. Stanga, Nutritional risk screening in cancer patients: the first step toward better clinical outcome. Front. Nutr. 8, 603936 (2021).","journal-title":"Front. Nutr."},{"key":"4228_CR10","first-page":"38","volume":"20","author":"J Ignacio de Ul\u00edbarri","year":"2005","unstructured":"J. Ignacio de Ul\u00edbarri, A. Gonz\u00e1lez-Madro\u00f1o, N.G. de Villar, P. Gonz\u00e1lez, B. Gonz\u00e1lez, A. Mancha, F. Rodr\u00edguez, G. Fern\u00e1ndez, CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr. Hosp. 20, 38\u201345 (2005).","journal-title":"Nutr. Hosp."},{"key":"4228_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2696-0","volume":"16","author":"T Toyokawa","year":"2016","unstructured":"T. Toyokawa, N. Kubo, T. Tamura, K. Sakurai, R. Amano, H. Tanaka, K. Muguruma, M. Yashiro, K. Hirakawa, M. Ohira, The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer 16, 722 (2016).","journal-title":"BMC Cancer"},{"key":"4228_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/00369330221122300","volume":"67","author":"J Ni","year":"2022","unstructured":"J. Ni, Y. Fang, J. Zhang, X. Chen, Predicting prognosis of heart failure using common malnutrition assessment tools: a systematic review and meta-analysis. Scott. Med. J. 67, 157\u2013170 (2022).","journal-title":"Scott. Med. J."},{"key":"4228_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1620\/tjem.224.215","volume":"224","author":"K Fukushima","year":"2011","unstructured":"K. Fukushima, Y. Ueno, N. Kawagishi, Y. Kondo, J. Inoue, E. Kakazu, M. Ninomiya, Y. Wakui, N. Saito, S. Satomi, T. Shimosegawa, The nutritional index \u2018CONUT\u2019 is useful for predicting long-term prognosis of patients with end-stage liver diseases. Tohoku J. Exp. Med. 224, 215\u2013219 (2011).","journal-title":"Tohoku J. Exp. Med."},{"key":"4228_CR14","first-page":"179","volume":"17","author":"JI de Ul\u00edbarri P\u00e9rez","year":"2002","unstructured":"J.I. de Ul\u00edbarri P\u00e9rez, A. Gonz\u00e1lez-Madro\u00f1o Gim\u00e9nez, P. Gonz\u00e1lez P\u00e9rez, G. Fern\u00e1ndez, F. Rodr\u00edguez Salvan\u00e9s, A. Mancha Alvarez-Estrada, A. D\u00edaz, Nuevo procedimiento para la detecci\u00f3n precoz y control de la desnutrici\u00f3n hospitalaria [New procedure for the early detection and control of hospital malnutrition]. Nutr. Hosp. 17, 179\u2013188 (2002).","journal-title":"Nutr. Hosp."},{"key":"4228_CR15","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1080\/01635581.2022.2059091","volume":"74","author":"J Chen","year":"2022","unstructured":"J. Chen, P. Song, Z. Peng, Z. Liu, L. Yang, L. Wang, J. Zhou, Q. Dong, The controlling nutritional status (CONUT) score and prognosis in malignant tumors: a systematic review and meta-analysis. Nutr. Cancer 74, 3146\u20133163 (2022).","journal-title":"Nutr. Cancer"},{"key":"4228_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3390\/cancers14030724","volume":"14","author":"C Dalmiglio","year":"2022","unstructured":"C. Dalmiglio, L. Brilli, M. Campanile, C. Ciuoli, A. Cartocci, M.G. Castagna, CONUT score: a new tool for predicting prognosis in patients with advanced thyroid cancer treated with TKI. Cancers 14, 724 (2022).","journal-title":"Cancers"},{"key":"4228_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"4228_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","volume":"118","author":"LD Locati","year":"2019","unstructured":"L.D. Locati, A. Piovesan, C. Durante, M. Bregni, M.G. Castagna, S. Zovato, M. Giusti, T. Ibrahim, E. Puxeddu, G. Fedele, G. Pellegriti, G. Rinaldi, D. Giuffrida, F. Verderame, F. Bertolini, C. Bergamini, A. Nervo, G. Grani, S. Rizzati, S. Morelli, I. Puliafito, R. Elisei, Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur. J. Cancer 118, 35\u201340 (2019).","journal-title":"Eur. J. Cancer"},{"key":"4228_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12020-020-02477-0","volume":"72","author":"S De Leo","year":"2021","unstructured":"S. De Leo, M. Di Stefano, L. Persani, L. Fugazzola, C. Colombo, Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. Endocrine 72, 462\u2013469 (2021).","journal-title":"Endocrine"},{"key":"4228_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1089\/thy.2020.0779","volume":"31","author":"MH Taylor","year":"2021","unstructured":"M.H. Taylor, S. Takahashi, J. Capdevila, M. Tahara, S. Leboulleux, N. Kiyota, C.E. Dutcus, R. Xie, B. Robinson, S. Sherman, M.A. Habra, R. Elisei, L.J. Wirth, Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 31, 1226\u20131234 (2021).","journal-title":"Thyroid"},{"key":"4228_CR21","doi-asserted-by":"publisher","first-page":"79884","DOI":"10.18632\/oncotarget.20168","volume":"8","author":"M Muscaritoli","year":"2017","unstructured":"M. Muscaritoli, S. Lucia, A. Farcomeni, V. Lorusso, V. Saracino, C. Barone, F. Plastino, S. Gori, R. Magarotto, G. Carteni, B. Chiurazzi, I. Pavese, L. Marchetti, V. Zagonel, E. Bergo, G. Tonini, M. Imperatori, C. Iacono, L. Maiorana, C. Pinto, D. Rubino, L. Cavanna, R. Di Cicilia, T. Gamucci, S. Quadrini, S. Palazzo, S. Minardi, M. Merlano, G. Colucci, P. Marchetti, PreMiO study group. prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget 8, 79884\u201379896 (2017).","journal-title":"Oncotarget"},{"key":"4228_CR22","first-page":"491","volume":"69","author":"WD Dewys","year":"1980","unstructured":"W.D. Dewys, C. Begg, P.T. Lavin, P.R. Band, J.M. Bennett, J.R. Bertino, M.H. Cohen, H.O. Douglass Jr, P.F. Engstrom, E.Z. Ezdinli, J. Horton, G.J. Johnson, C.G. Moertel, M.M. Oken, C. Perlia, C. Rosenbaum, M.N. Silverstein, R.T. Skeel, R.W. Sponzo, D.C. Tormey, Prognostic effect of weight loss prior to chemotherapy in cancer patients. East. Cooperative Oncol. Group. Am. J. Med. 69, 491\u2013497 (1980).","journal-title":"East. Cooperative Oncol. Group. Am. J. Med."},{"key":"4228_CR23","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1080\/01635581.2023.2227402","volume":"75","author":"Y Zang","year":"2023","unstructured":"Y. Zang, W. Xu, Y. Qiu, D. Gong, Y. Fan, Association between risk of malnutrition defined by the nutritional risk screening 2002 and postoperative complications and overall survival in patients with cancer: a meta-analysis. Nutr. Cancer 75, 1600\u20131609 (2023).","journal-title":"Nutr. Cancer"},{"key":"4228_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijsu.2019.05.018","volume":"67","author":"X Wang","year":"2019","unstructured":"X. Wang, Y. Wang, The prognostic nutritional index is prognostic factor of gynecological cancer: a systematic review and meta-analysis. Int. J. Surg. 67, 79\u201386 (2019).","journal-title":"Int. J. Surg."},{"key":"4228_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/advances\/nmaa102","volume":"12","author":"S Kheirouri","year":"2021","unstructured":"S. Kheirouri, M. Alizadeh, Prognostic potential of the preoperative controlling nutritional status (CONUT) score in predicting survival of patients with cancer: a systematic review. Adv. Nutr. 12, 234\u2013250 (2021).","journal-title":"Adv. Nutr."},{"key":"4228_CR26","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.3390\/jcm12186017","volume":"12","author":"E Gremese","year":"2023","unstructured":"E. Gremese, D. Bruno, V. Varriano, S. Perniola, L. Petricca, G. Ferraccioli, Serum albumin levels: a biomarker to be repurposed in different disease settings in clinical practice. J. Clin. Med. 12, 6017 (2023).","journal-title":"J. Clin. Med."},{"key":"4228_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2019.10.031","volume":"133","author":"A Eckart","year":"2020","unstructured":"A. Eckart, T. Struja, A. Kutz, A. Baumgartner, T. Baumgartner, S. Zurfluh, O. Neeser, A. Huber, Z. Stanga, B. Mueller, P. Schuetz, Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a prospective study. Am. J. Med. 133, 713\u2013722.e7 (2020).","journal-title":"Am. J. Med."},{"key":"4228_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cca.2017.11.039","volume":"477","author":"P Zhou","year":"2018","unstructured":"P. Zhou, B. Li, B. Liu, T. Chen, J. Xiao, Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: a systematic review and meta-analysis. Clin. Chim. Acta 477, 94\u2013104 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"4228_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","volume":"2","author":"B Huang","year":"2020","unstructured":"B. Huang, B.L. Song, C. Xu, Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat. Metab. 2, 132\u2013141 (2020).","journal-title":"Nat. Metab."},{"key":"4228_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"X. Ma, E. Bi, Y. Lu, P. Su, C. Huang, L. Liu, Q. Wang, M. Yang, M.F. Kalady, J. Qian, A. Zhang, A.A. Gupte, D.J. Hamilton, C. Zheng, Q. Yi, Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab. 30, 143\u2013156.e5 (2019).","journal-title":"Cell Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04228-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04228-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04228-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:49:11Z","timestamp":1751611751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04228-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4228"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04228-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}